DanQi Pill protects against heart failure through the arachidonic acid metabolism pathway by attenuating different cyclooxygenases and leukotrienes B4

BMC Complementary and Alternative Medicine

Volumn 14, Issue , 2014, Pages

  Wang, Yong ^a   Li, Chun ^a   Liu, Zhongyang ^b   Shi, Tianjiao ^a   Wang, Qiyan ^a   Li, Dong ^b   Wu, Yan ^a   Han, Jing ^a   Guo, Shuzhen ^a   Tang, Binghua ^a   Wang, Wei ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTONIC AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HERBACEOUS AGENT; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR; PROSTACYCLIN; THROMBOXANE B2;

ANIMAL; CHINESE MEDICINE; HEART FAILURE; MALE; METABOLISM; PANAX NOTOGINSENG; PHYTOTHERAPY; SALVIA MILTIORRHIZA; SPRAGUE DAWLEY RAT;

ANIMALS; CARDIOTONIC AGENTS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DRUGS, CHINESE HERBAL; EPOPROSTENOL; HEART FAILURE; LEUKOTRIENE B4; MALE; MEDICINE, CHINESE TRADITIONAL; PANAX NOTOGINSENG; PHYTOTHERAPY; RATS, SPRAGUE-DAWLEY; RECEPTORS, LEUKOTRIENE B4; SALVIA MILTIORRHIZA; THROMBOXANE B2;

EID: 84894420946     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-14-67     Document Type: Article

References (44)

1. Panza JA, Holly TA, Asch FM, She L, Pellikka PA, Velazquez EJ, Lee KL, Borges-Neto S, Farsky PS, Jones RH, Berman DS, Bonow RO. Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 2013, 61:1860-1870. 10.1016/j.jacc.2013.02.014, 23500234.
2. Bozkurt B, Mann DL, Deswal A. Biomarkers of inflammation in heart failure. Heart Fail Rev 2010, 15:331-341. 10.1007/s10741-009-9140-3, 19363700.
3. Saito T, Rodger IW, Hu F, Robinson R, Huynh T, Giaid A. Inhibition of COX pathway in experimental myocardial infarction. J Mol Cell Cardiol 2004, 37:71-77. 10.1016/j.yjmcc.2004.04.002, 15242737.
4. Amer M, Bead VR, Bathon J, Blumenthal RS, Edwards DN. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiol Rev 2010, 18:204-212. 10.1097/CRD.0b013e3181ce1521, 20539104.
5. Li X, Zhang J, Huang J, Ma A, Yang J, Li W, Wu Z, Yao C, Zhang Y, Yao W, Zhang B, Gao R, Efficacy and Safety of Qili Qiangxin Capsules for Chronic Heart Failure Study Group A multicenter randomized double-blind parallel-group placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol 2013, 62:065-1072. Efficacy and Safety of Qili Qiangxin Capsules for Chronic Heart Failure Study Group.
6. Ministry of Health of the People's Republic of China Pharmacopoeia Committee China pharmaceutical standards for formulations and the drug prescription of the ministry of health of the People's Republic. Chin Med Sci Technol Press 2010, 1:107-116. Ministry of Health of the People's Republic of China Pharmacopoeia Committee.
7. Gong DK, Zhang XM. Clinical effect observation on the treatment of Dan QI Pian on coronary heart disease. Chin J Ethnomed Ethnopharm 2009, 7:125-126.
8. Chen S, Liu J, Liu X, Fu Y, Zhang M, Lin Q, Zhu J, Mai L, Shan Z, Yu X, Yang M, Lin S. Panax notoginseng saponins inhibit ischemia-induced apoptosis by activating PI3K/Akt pathway in cardiomyocytes. J Ethnopharmacol 2011, 137:263-270. 10.1016/j.jep.2011.05.011, 21619920.
9. Tu EY, Zhou YG, Wang ZH, Liang QS, Yang GT. Effects of tanshinone II A on the myocardial hypertrophy signal transduction system protein kinase B in rats. Chin J Integr Med 2009, 15:365-370. 10.1007/s11655-009-0365-8, 19802541.
10. Parsons AB, Brost RL, Ding H, Li Z, Zhang C, Sheikh B, Brown GW, Kane PM, Hughes TR, Boone C. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat Biotechnol 2003, 22:62-69.
11. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935. 10.1126/science.1132939, 17008526.
12. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 2008, 321:263-266. 10.1126/science.1158140, 18621671.
13. Nidhi, Glick M, Davies JW, Jenkin JL. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J Chem Inf Model 2006, 46:1124-1133. 10.1021/ci060003g, 16711732.
14. Cheng AC, Coleman RG, Smyth KT, Cao Q, Soulard P, Caffrey DR, Salzberg AC, Huang ES. Structure based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 2007, 25:71-75. 10.1038/nbt1273, 17211405.
15. Bleakley K, Yamanishi Y. Supervised prediction of drug-target interactions using bipartite local models. Bioinformatics 2009, 25:2397-2403. 10.1093/bioinformatics/btp433, 2735674, 19605421.
16. Zhao S, Li S. Network-based relating pharmacological and genomic spaces for drug target identification. PLoS One 2010, 5:e11764. 10.1371/journal.pone.0011764, 2909904, 20668676.
17. Wang Y, Liu Z, Li C, Li D, Ouyang Y, Yu J, Guo S, He F, Wang W. Drug target prediction based on the herbs components: the study on the multitargets pharmacological mechanism of qishenkeli acting on the coronary heart disease. Evid Based Complement Alternat Med 2012, 2012:1-10.
18. PeiGen X. The Modern Chinese Materia Medica 2007, Bei Jing: Chemical Industry Press.
19. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008, 36:901-906.
20. Bender A, Mussa Y, Glen RC, Reiling S. Molecular Similarity searching using atom environments, information-based feature selection, and a naïve bayesian classifier. J Chem Inf Comput Sci 2004, 44:170-178. 10.1021/ci034207y, 14741025.
21. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A, Balakrishnan L, Marimuthu A, Banerjee S, Somanathan DS, Sebastian A, Rani S, Ray S, Harrys Kishore CJ, Kanth S, Ahmed M, Kashyap MK, Mohmood R, Ramachandra YL, Krishna V, Rahiman BA, Mohan S, Ranganathan P, Ramabadran S, Chaerkady R, Pandey A. Human protein reference database - 2009 update. Nucleic Acids Res 2009, 37:767-772.
22. Zhao J, Ding GH, Tao L, Yu H, Yu ZH, Luo JH, Cao ZW, Li YX. Modular co-evolution of metabolic networks. BMC Bioinformatics 2007, 8:311. 10.1186/1471-2105-8-311, 2001200, 17723146.
23. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet 2000, 25:25-29. 10.1038/75556, 3037419, 10802651.
24. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000, 28:27-30. 10.1093/nar/28.1.27, 102409, 10592173.
25. Pinto YM, de Smet BG, van Gilst WH, Scholtens E, Monnink S, de Graeff PA, Wesseling H. Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. Cardiovasc Res 1993, 27:1933-1938. 10.1093/cvr/27.11.1933, 8287399.
26. Wei J, Ramanathan P, Martin IC, Moran C, Taylor RM, Williamson P. Identification of gene sets and pathways associated with lactation performance in mice. Physiol Genomics 2013, 45:171-181. 10.1152/physiolgenomics.00139.2011, 23284081.
27. Wang Y, Yu X, Wang F, Wang Y, Wang Y, Li H, Lv X, Lu D, Wang H. Yohimbine promotes cardiac NE release and prevents LPS-induced cardiac dysfunction via blockade of presynaptic α2A-adrenergic receptor. PLoS One 2013, 8:e63622. 10.1371/journal.pone.0063622, 3653853, 23691077.
28. Vázquez-Medina JP, Popovich I, Thorwald MA, Viscarra JA, Rodriguez R, Sonanez-Organis JG, Lam L, Peti-Peterdi J, Nakano D, Nishiyama A, Ortiz RM. Angiotensin receptor mediated oxidative stress is associated with impaired cardiac redox signaling and mitochondrial function in insulin resistant rats. Am J Physiol Heart Circ Physiol 2013, [Epub ahead of print].
29. Roh J, Chang CL, Bhalla A, Klein C, Hsu SY. Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem 2004, 279:7264-7274.
30. Zhao MW, Wang ED. Regulation of angiogenic signaling pathway by two human aminoacyl-tRNA synthetases. Prog Biochem Biophys 2003, 30:689-693.
31. Cain AE, Tanner DM, Khalil RA. Endothelin-1-induced enhancement of coronary smooth muscle contraction via MAPK-dependent and MAPK-independent [Ca2+] sensitization pathways. Hypertension 2002, 39:543-549. 10.1161/hy0202.103129, 11882605.
32. Neutel JM. Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacologyto clinical efficacy. Curr Med Res Opin 2010, 26:213-223. 10.1185/03007990903444434, 19921961.
33. Levick SP, Loch DC, Taylor SM, Janicki JS. Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. J Immunol 2007, 178:641-646.
34. Ramli J, CalderonArtero P, Block RC, Mousa1 SA. Novel therapeutic targets for preserving a healthy endothelium: strategies for reducing the risk of vascular and cardiovascular disease. Cardiol J 2011, 18:352-363. 3342824, 21769815.
35. Konya V, Marsche G, Schuligoi R, Heinemann A. E-type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacol Ther 2013, 138:485-502. 10.1016/j.pharmthera.2013.03.006, 3661976, 23523686.
36. Dd Fortier MA, Krishnaswamy K, Danyod G, Boucher-Kovalik S, Chapdalaine P. A postgenomic integrated view of prostaglandins in reproduction: implications for other body systems. J Physiol Pharmacol 2008, 59(Suppl 1):65-89.
37. Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2011, 103:1227-1237.
38. Ruan CH, So SP, Ruan KH. Inducible COX2 dominates over COX1 in prostacyclin biosynthesis: mechanisms of COX2 inhibitor risk to heart disease. Life Sci 2011, 88:24-30. 10.1016/j.lfs.2010.10.017, 3046773, 21035466.
39. Astudillo AM, Balgoma D, Balboa MA, Balsinde J. Dynamics of arachidonic acid mobilization by inflammatory cells. Biochim Biophys Acta 1821, 2012:249-256.
40. de Gaetano G, Donati MB, Cerletti C. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX1, COX2 and 5-LOX inhibitors. Trends Pharmacol Sci 2003, 24:245-252. 10.1016/S0165-6147(03)00077-4, 12767724.
41. Yuhki K, Kashiwagi H, Kojima F, Kawabe J, Ushikubi F. Roles of prostanoids in the pathogenesis of cardiovascular diseases. Int Angiol 2010, 29:19-27.
42. Waki H, Hendy EB, Hindmarch CC, Gouraud S, Toward M, Kasparov S, Murphy D, Paton JF. Excessive leukotriene B4 in nucleus tractus solitarii is prohypertensive in spontaneously hypertensive rats. Hypertension 2013, 61:194-201. 10.1161/HYPERTENSIONAHA.112.192252, 23172924.
43. 4 formation from neutrophils in patients treated with coronary bypass surgery: a randomized placebo-controlled double-blinded trial with a crossover design. Prostaglandins Leukot Essent Fatty Acids 2012, 87:185-188. 10.1016/j.plefa.2012.09.004, 23063168.
44. Liu D, Ji L, Wang Y, Zheng L. Cyclooxygenase-2 expression, prostacyclin production and endothelial protection of high-density lipoprotein. Cardiovasc Hematol Disord Drug Targets 2012, 12:98-105. 10.2174/1871529X11202020098, 23030452.